NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma.
Eudocia Quant LeePeixin ZhangPatrick Y WenElizabeth R GerstnerDavid A ReardonKenneth D AldapeJohn F deGrootEdward PanJeffrey J RaizerLyndon J KimSteven J ChmuraH Ian RobinsJennifer M ConnellyJames D BattisteJohn L VillanoNaveed WagleRyan T MerrellMerideth M WendlandMinesh P MehtaPublished in: Cancer (2020)
The combination of bevacizumab and trebananib was well tolerated but did not significantly improve 6-month PFS rate, PFS, or OS for patients with rGBM over bevacizumab alone. The shorter PFS in the experimental arm with a hazard ratio of 1.51 (P = .04) suggests that the addition of trebananib to bevacizumab is detrimental.
Keyphrases